Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation

Background. Diabetes Mellitus Type 2 (DMT2) is a complex medical and social problem in the world and in the Russian Federation also due to prevalence and probability of cardio-vascular complications (CVC).Aim. Economic burden evaluation of DMT2 in the Russian Federation.Methods. Complex analysis of...

Full description

Saved in:
Bibliographic Details
Main Authors: Ivan I. Dedov, Anna V. Koncevaya, Marina V. Shestakova, Yuriy B. Belousov, Julia A. Balanova, Mikhail B. Khudyakov, Oleg I. Karpov
Format: Article
Language:English
Published: Endocrinology Research Centre 2016-12-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/8153
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850254424674402304
author Ivan I. Dedov
Anna V. Koncevaya
Marina V. Shestakova
Yuriy B. Belousov
Julia A. Balanova
Mikhail B. Khudyakov
Oleg I. Karpov
author_facet Ivan I. Dedov
Anna V. Koncevaya
Marina V. Shestakova
Yuriy B. Belousov
Julia A. Balanova
Mikhail B. Khudyakov
Oleg I. Karpov
author_sort Ivan I. Dedov
collection DOAJ
description Background. Diabetes Mellitus Type 2 (DMT2) is a complex medical and social problem in the world and in the Russian Federation also due to prevalence and probability of cardio-vascular complications (CVC).Aim. Economic burden evaluation of DMT2 in the Russian Federation.Methods. Complex analysis of expenditures (direct and non-direct costs) based on epidemiological, pharmacoeconomics and clinical investigations, population and medical statistics data.Results. Calculated expenditures for DMT2 are 569 bln RUR per year, that is correspond to 1% of the Russian GDP, and 34,7% of that are expenditures for main CVC (ischemic heart disease, cardiac infarction, stroke). Main part of expenses are non-medical (losses GDP) due to temporary and permanent disability, untimely mortality – 426,7 bln RUR per year. Expenditures in estimated group of patients with non-diagnosed DMT2 but with already having CVC were at least 107 bln per year (18,8% from total cost). Relationship between cost of DMT2 and degree of it’s control was found in the Russian conditions. Estimated cost for compensated patient (HbA1c<6,5%) per year was 88 982 RUR, in the same time cost of non-control patient (HbA1c>9,5%) was in 2,8 times higher due to more often main CVC in this group.Conclusion. DMT2 diagnosis improvement as well as effective treatment of early stages of illness can decrease probability of CVC and social economic expenditures.
format Article
id doaj-art-91b40641d3e84f8ab2e700fb69ae0e9f
institution OA Journals
issn 2072-0351
2072-0378
language English
publishDate 2016-12-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj-art-91b40641d3e84f8ab2e700fb69ae0e9f2025-08-20T01:57:08ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782016-12-0119651852710.14341/DM81537541Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian FederationIvan I. Dedov0Anna V. Koncevaya1Marina V. Shestakova2Yuriy B. Belousov3Julia A. Balanova4Mikhail B. Khudyakov5Oleg I. Karpov6Endocrinology Research CentreState Research Center of Preventive MedicineEndocrinology Research Centre; I.M. Sechenov First Moscow State Medical UniversityN.I. Pirogov Russian National Research Medical UniversityState Research Center of Preventive MedicineState Research Center of Preventive MedicineSanofiBackground. Diabetes Mellitus Type 2 (DMT2) is a complex medical and social problem in the world and in the Russian Federation also due to prevalence and probability of cardio-vascular complications (CVC).Aim. Economic burden evaluation of DMT2 in the Russian Federation.Methods. Complex analysis of expenditures (direct and non-direct costs) based on epidemiological, pharmacoeconomics and clinical investigations, population and medical statistics data.Results. Calculated expenditures for DMT2 are 569 bln RUR per year, that is correspond to 1% of the Russian GDP, and 34,7% of that are expenditures for main CVC (ischemic heart disease, cardiac infarction, stroke). Main part of expenses are non-medical (losses GDP) due to temporary and permanent disability, untimely mortality – 426,7 bln RUR per year. Expenditures in estimated group of patients with non-diagnosed DMT2 but with already having CVC were at least 107 bln per year (18,8% from total cost). Relationship between cost of DMT2 and degree of it’s control was found in the Russian conditions. Estimated cost for compensated patient (HbA1c<6,5%) per year was 88 982 RUR, in the same time cost of non-control patient (HbA1c>9,5%) was in 2,8 times higher due to more often main CVC in this group.Conclusion. DMT2 diagnosis improvement as well as effective treatment of early stages of illness can decrease probability of CVC and social economic expenditures.https://www.dia-endojournals.ru/jour/article/view/8153diabetes mellitus type 2health care system economicscost of illness
spellingShingle Ivan I. Dedov
Anna V. Koncevaya
Marina V. Shestakova
Yuriy B. Belousov
Julia A. Balanova
Mikhail B. Khudyakov
Oleg I. Karpov
Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation
Сахарный диабет
diabetes mellitus type 2
health care system economics
cost of illness
title Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation
title_full Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation
title_fullStr Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation
title_full_unstemmed Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation
title_short Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation
title_sort economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the russian federation
topic diabetes mellitus type 2
health care system economics
cost of illness
url https://www.dia-endojournals.ru/jour/article/view/8153
work_keys_str_mv AT ivanidedov economicevaluationoftype2diabetesmellitusburdenanditsmaincardiovascularcomplicationsintherussianfederation
AT annavkoncevaya economicevaluationoftype2diabetesmellitusburdenanditsmaincardiovascularcomplicationsintherussianfederation
AT marinavshestakova economicevaluationoftype2diabetesmellitusburdenanditsmaincardiovascularcomplicationsintherussianfederation
AT yuriybbelousov economicevaluationoftype2diabetesmellitusburdenanditsmaincardiovascularcomplicationsintherussianfederation
AT juliaabalanova economicevaluationoftype2diabetesmellitusburdenanditsmaincardiovascularcomplicationsintherussianfederation
AT mikhailbkhudyakov economicevaluationoftype2diabetesmellitusburdenanditsmaincardiovascularcomplicationsintherussianfederation
AT olegikarpov economicevaluationoftype2diabetesmellitusburdenanditsmaincardiovascularcomplicationsintherussianfederation